人工心肺後の腎機能障害に対するNFκB inhibitorの腎保護効果の検討と分子機序の解明

• Project/Area Number: 25K12189
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55050:Anesthesiology-related
• Research Institution: Sapporo Medical University
• Principal Investigator: 大野 翔 札幌医科大学, 医学部, 研究員 (10882904)
• Project Period (FY): 2025-04-01 – 2028-03-31
• Project Status: Granted (Fiscal Year 2025)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2027: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000); Fiscal Year 2026: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2025: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
• Keywords: 人工心肺 / 急性腎障害

Outline of Research at the Start

NFκB inhibitorであるDHMEQを投与し，NFκB signaling pathwayを制御することでその下流である炎症系のpathwayやアポトーシスを抑制し，腎保護効果につながるかをラット人工心肺-AKIモデルで検討する．